Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database

Journal of Managed Care Pharmacy

Volumn 13, Issue 1, 2007, Pages 44-52

  Prescott, Jeff D ^a   Factor, Saul ^b,c   Pill, Michael ^a   Levi, Gary W ^a  

^a The MCM Group   (United States)

^b McKesson   (United States)

^c RxAmerica LLC   (United States)

Author keywords

Benchmarking; Managed care; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA; BURNING SENSATION; CHILD; COMORBIDITY; COMPUTER PROGRAM; CONVULSION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DESCRIPTIVE RESEARCH; DRUG COST; EMERGENCY HEALTH SERVICE; FATIGUE; FECES INCONTINENCE; FEMALE; FIBROMYALGIA; GAIT DISORDER; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; INFANT; LARYNX DISORDER; MAJOR CLINICAL STUDY; MALAISE; MALE; MANAGED CARE; MULTIPLE SCLEROSIS; MUSCLE SPASM; MYALGIA; MYOSITIS; OPTIC NEURITIS; OUTPATIENT CARE; PARESTHESIA; REIMBURSEMENT; SKIN TINGLING; TRIGEMINUS NEURALGIA; URINE INCONTINENCE;

EID: 34249723173     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.1.44     Document Type: Article

References (13)

1. Hauser SL, Goodkin DE. Multiple sclerosis and other demyelinating diseases. In: Braunwald E, et al, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw Hill; 2001:2452-61.
2. Frohman EM. Multiple sclerosis. Med Clin North Am. 2003;87:867-97.
3. Ryan M, Piascik P. Providing pharmaceutical care to the multiple sclerosis patient. J Am Pharm Assoc. 2002;42:753-67.
4. Wingerchuk DM, Weinshenker BG. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures. Adv Mult Scler. 2000;10:611-23.
5. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4:419-25.
6. Symmetry-Health corporate Web site. Available at: http://www.symmetryhealth.com. Accessed August 31, 2006.
7. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilder T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology. 2002;58(1):37-43.
8. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;13(66):1696-1702.
9. Patwardhan MB, Matchar DB, Samsa GP, McCrory C, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11(2):232-39.
10. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17.
11. Coleman IC, Cook R, Gade JN, et al. Meeting the challenge of incorporating injectable biologics into managed care: multiple sclerosis and psoriasis. J Manag Care Pharm 2004;10(3)(suppl S-b):S1-S45. Available at: http://www.amcp.org/data/jmcp/June04Supplement1.pdf. Accessed August 31, 2006.
12. National Institute for Clinical Excellence. Technology appraisal of beta interferon and glatiramer acetate for MS. Available at: http://www.nice.org.uk/page.aspx?o=ta032. Accessed August 31, 2006.
13. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;(8)6:469-76. Available at: http://www.amcp.org/data/jmcp/ Research469-476.pdf. Accessed August 31, 2006.